× Industry Reports Services Press Release Contact us About us

North America Regenerative Medicine Market Forecast 2027 By Application (Oncology, Dermatology, Musculoskeletal, Neurology, Cardiovascular, Wound Healing, Ophthalmology) By Type (Cell therapy, Tissue Engineering, Gene Therapy), Research Report, Country Outlook (U.S., Canada), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share
Published Date: October 2021 | Publisher: Graphical Research Report ID: GR1979 | Delivery : PDF  Request Free Sample

North America Regenerative Medicine Market size surpassed USD 17 billion in 2020 and is expected to witness 18.5% CAGR from 2021 to 2027.

Increasing incidence of organ failure coupled with growing awareness among population are the factors augmenting the market growth. Organ failure among population is majorly due to several health conditions such as heart diseases, severe infection among other factors that increase demand for organ transplant. Additionally, regenerative medicines are widely used in transplant procedures as it is an interdisciplinary field and a branch of translational research that helps to promote regeneration and restore damaged tissues or entire organs.

North America Regenerative Medicine Market

Get more details on this report - Request Free Sample PDF

Growing prevalence of chronic diseases along with increasing investment in regenerative medicine research will stimulate the regenerative medicine market expansion in the North America region. Chronic diseases such as cancer, diabetes, cardiovascular, ulcer, and genetic disorders are growing significantly. Regenerative medicines have the potency to treat diabetes by regaining insulin function in patients. According to the CDC, approximately 26.9 million people are diagnosed with diabetes in U.S. and account for around 10.5% of total U.S. population. Further, regenerative medicine has also been used in cardiovascular diseases including congenital heart disease.

North America Market, By Type

Cell therapy segment will observe around 18% growth rate during the forecast period, led by growing number of clinical studies for cell therapies. For instance, in February 2021, RepliCel announced the commercialization and clinical testing of additional 3 technologies in Japan. These technologies include two cell-based therapies and one for skin regeneration and the other for tendon rejuvenation.

North America Market, By Application

Musculoskeletal segment held over 30% North America regenerative medicine market share in 2020. Growing prevalence of orthopedic conditions along with the increasing elderly population base will impel the market demand. According to the Population Reference Bureau, population aged 65 and older is estimated to nearly double from 52 million in 2018 to 95 million by 2060.

North America Market, By Country

U.S. regenerative medicine market accounted for USD 15 billion revenue in 2020, due to high spending on healthcare and disposable income in the country. Adding to this, increasing healthcare funding as well as numerous initiatives by the government & private research organizations contributes to the strengthen market size. For instance, in 2020, the U.S. Department of Health and Human Services initiated A New Vision to recognize regenerative medicine at the lead of healthcare.

Competitive Industry Landscape

Key players engaged in the market include AbbVie Inc (Allergan Plc), Osiris Therapeutics (Smith & Nephew), and Bristol Myers Squibb. These firms are adopting various strategies to generate greater market share through augmentation of portfolio with novel applications. For instance, in February 2021, Bristol Myers Squibb received the U.S. FDA approval for its product Breyanzi. It is indicated for adults with relapsed or refractory (R/R) large B-cell lymphoma (LBCL). This approval will assist the company to expand its product offerings and strengthen its position in market.

Frequently Asked Question(FAQ) :

The market size for regenerative medicine in North America had exceeded USD 17 billion in 2020 and will witness a CAGR of 18.5% through 2027 with the rising cases of organ failure in the region.
Cell therapy segment will observe a CAGR of over 18% through 2027 with the rising number of clinical studies for cell therapies.
Musculoskeletal segment had captured over 30% share in 2020 owing to rising prevalence of orthopedic conditions coupled with the increasing elderly population in the region.
The market size for regenerative medicine in U.S. had surpassed USD 15 billion in 2020 owing to the increasing healthcare expenditure and rising disposable income in the country.
The key players engaged in the market are AbbVie Inc (Allergan Plc), Osiris Therapeutics (Smith & Nephew), and Bristol Myers Squibb.

Premium Report

Have questions?
  • Inquire Before Buying
  • Why Choose us?

    • on-time delivery On-Time Delivery

      We commit to on-time delivery of reports to keep you ahead.

    • assured quality Assured Quility

      With a wide network of industry experts and trained in-house analysts, we assure best service quality.

    • Custom Research Service

      We offer research services to meet specific client requirements and provide them with actionable insights on target markets.

    • payment security Payment Security

      Our safe payment gateway gives you full control of your personal data, at all times.

    Connect with our sales team

     1-800-986-6917

     [email protected]